Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Patients with Rheumatic Disease May Experience Flares after SARS-CoV-2 Vaccination

Linda Carroll  |  July 12, 2021

(Reuters Health)—Among a group of New York patients with rheumatic diseases who received a SARS-CoV-2 vaccine, nearly one in six experienced disease flares after getting their shots, a new study finds.1

A survey of more than 1,100 patients who had received at least one vaccine dose revealed that 14.9% experienced flares. Among the 654 who had received both doses of a Pfizer or Moderna vaccine, 113 (17%) flared, with 26 (23%) flaring only after the first dose, 48 (42.5%) flaring only after the second dose and 37 (32.7%) flaring after both doses, according to the letter in Annals of the Rheumatic Diseases.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“This information is reassuring and can help inform vaccine decision-making for patients with systemic rheumatic diseases,” the researchers, led by Dr. Medha Barbhaiya of the division of rheumatology at the Hospital for Special Surgery, New York, write in their report. “Although we did not collect laboratory studies, most systemic rheumatic disease flares were described as ‘typical’, suggesting these symptoms are not vaccine’s adverse effects being misreported as disease flares.”

“However, when patients did flare, the majority of flares were reported as moderate to severe, with some lasting more than three weeks,” the authors note. “Therefore, it will be important to follow these patients prospectively, as well as to perform analyses which incorporate potential confounders to identify predictors of systemic rheumatic disease flares post-vaccination.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“Our study assessed self-reported disease flares and was not designed to correlate disease flares with biological markers,” says lead author Medha Barbhaiya, MD, MPH, of the Division of Rheumatology, Hospital for Special Surgery, New York, in an email. “Regardless, our data provides reassurance to physicians and patients that the rate of self-reported flares after COVID-19 vaccination by patients with systemic rheumatic diseases appears relatively low.”

To explore whether the SARS-CoV02 vaccines might trigger flares, Dr. Barbhaiya and colleagues emailed a survey on March 5, 2021, to 3,545 outpatients with systemic rheumatic disease.

As of April 12, 2021, 1,483 patients responded, with 1,101 (74.2%) saying they had received at least one dose of a COVID-19 vaccine and reporting whether they had experienced flares. Just 16 (1.5%) had received the Johnson & Johnson vaccine and three (0.3%) received the AstraZeneca vaccine. The rest had received either the Pfizer (54.2%) or Moderna (43.9%) vaccines.

Among patients receiving either Pfizer or Moderna vaccines, 654 (59.4%) had received both doses.

A total of 202 systemic rheumatic disease flares were reported by 165 patients (14.9%). A history of suspected/confirmed COVID-19 occurred in 7.9% with systemic rheumatic disease flare and 6.7% without systemic rheumatic disease flare. The mean age of patients reporting a systemic rheumatic disease flare was 59.6 versus 61.0 years in the non-flare group.

Both the flare and non-flare groups used medications, such as Benadryl, acetaminophen or NSAIDs, for prevention and treatment of vaccine side effects.

Most systemic rheumatic disease flares were described as moderate to severe and appeared to be typical systemic rheumatic disease flares. Symptoms reported during flares included joint pain, joint swelling, muscle aches and fatigue. Although 27.7% of flares started one day after vaccination, 61.4% began after two to seven days and 10.9% occurred more than seven days post vaccination. Most systemic rheumatic disease flares resolved within seven days of onset, but 26.2% lasted for 8–21 days and 8.9% for more than 21 days.

One thing you can’t tell from this study is whether the patients temporarily discontinued their regular medications prior to vaccination, says Weiwei Chi, MD, an assistant professor of medicine in the division of rheumatology at the Icahn School of Medicine at Mount Sinai, New York.

“We have older studies that say, for example, that methotrexate can affect responses to flu vaccines,” Dr. Chi says. “Some providers recommend holding methotrexate for a few weeks after vaccination to have the best protection.”

Another issue with the study is that they seem to have lumped together several autoimmune diseases, Dr. Chi says. “When you lump everyone together it’s really hard to draw conclusions.”

In the end, this is a risk-benefit calculation, Dr. Chi says. “If you get COVID, it can be devastating and potentially fatal,” she adds. “In a sense, maybe the risk of a flare is worth it, when you’re comparing the long-term consequences of a flare versus a severe case of COVID-19 or long-hauler symptoms.”

“Overall, I think it’s good to have this as a starting point,” Dr. Chi says. “But I wouldn’t take the results to mean that everyone needs to be really careful about vaccinating patients with autoimmune diseases.”


Reference

  1. Barbhaiya M, Levine JM, Bykerk VP, et al. Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City. Ann Rheum Dis. 2021 Jun 22;annrheumdis-2021-220732. Online ahead of print.

Page: 1 2 | Multi-Page
Share: 

Filed under:Conditions Tagged with:COVID-19FlaresSARS-CoV-2Systemic Rheumatic Diseasesvaccinationvaccine

Related Articles

    Vax Hesitancy? Myths & Facts for Patients

    December 16, 2021

    Lia Kos / shutterstock.com Although more than 189,300,000 eligible Americans are fully vaccinated against SARS-CoV-2 as of Oct. 18, 2021, vaccine hesitancy persists.1 The U.S. Centers for Disease Control and Prevention (CDC), citing data from the U.S. Census Bureau’s Household Pulse Survey collected between May 26 and June 7, 2021, reports that in some U.S….

    Vaccine Hesitancy: Wariness Is Rare, But There’s a Wider Worry About COVID Vaccines’ Efficacy in Some Populations

    July 6, 2021

    Hesitancy about COVID-19 vaccination persists nationwide, although it varies among regions and sociodemographic groups.

    The End of the Beginning: COVID-19 Vaccines & Other Conundrums

    December 9, 2020

    Phil Seo, MD, MHS “It’s like winning Powerball.” For months, there has been a steady trickle of questions from my patients, asking for my opinion about the new vaccines being developed to prevent COVID-19. More to the point, they want to know if they should be vaccinated. ad goes here:advert-1ADVERTISEMENTSCROLL TO CONTINUEAfter some fits and…

    Anze Furlan / SHUTTERSTOCK.COM

    How Immunosuppression May Affect COVID-19 Vaccine Response

    June 13, 2021

    Although we can expect to learn much more, preliminary data are now available on the potential safety and effectiveness of COVID-19 vaccines in rheumatology patients. The picture is likely to be nuanced, with not all types of immuno­suppressive treatments having identical impacts on vaccine response. Rheumatologists should use caution in interpreting early reports, while continuing…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences